| Patents for C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof (42,273) |
|---|
| 02/09/2006 | US20060029638 Methods for treating body tissue |
| 02/09/2006 | US20060029545 Metal radionuclide complexed directly to a an annexin that has been modified to add a sulfhydryl group which participates in the complexation of the metal radionuclide; useful for imaging vascular thrombi |
| 02/09/2006 | US20060029544 Receptor-binding cyclic peptides and methods of use |
| 02/09/2006 | CA2574605A1 Cyclic peptides for treatment of cachexia |
| 02/09/2006 | CA2573142A1 Cyclic peptides for treatment of cachexia |
| 02/08/2006 | EP1623994A2 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 02/08/2006 | EP1623036A2 Identification of novel nogo-receptors and methods related thereto |
| 02/08/2006 | EP1622931A1 Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity |
| 02/08/2006 | EP1622930A1 Template-fixed peptidomimetics as medicaments against hiv and cancer |
| 02/08/2006 | EP1622563A2 Improved heat shock protein-based vaccines and immunotherapies |
| 02/08/2006 | EP0988045B1 Peptide nucleic acid monomers and oligomers |
| 02/08/2006 | EP0969855B1 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 02/08/2006 | EP0948343B1 Alkyl peptide amides adapted for topical administration |
| 02/08/2006 | CN1732016A Modified cytokines for use in cancer therapy |
| 02/08/2006 | CN1732013A Desamino-8-a-arginyl vasopressin analogs |
| 02/08/2006 | CN1730488A Peptides for promoting platelet growth, accumulation and suppressing hypertension and its uses |
| 02/08/2006 | CN1240713C New compound |
| 02/07/2006 | US6995238 Cyclopeptide derivatives |
| 02/07/2006 | US6995139 Cyclic undecapeptide pro-drugs and uses thereof |
| 02/07/2006 | US6995135 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments |
| 02/07/2006 | US6994982 Isolating biological modulators from biodiverse gene fragment libraries |
| 02/07/2006 | US6994970 Peptides which bind auto-antibodies for use in extracorporeal treatment; peptides bound to solid support for chromatography; specified amino acid sequence |
| 02/07/2006 | CA2026147C Cytotoxic agents comprising maytansinoids and their therapeutic use |
| 02/02/2006 | WO2005090387A3 Histone h2a peptide derivatives and analogs and methods of use thereof |
| 02/02/2006 | WO2005084266A3 Functional method for generating or screening for ligands which modulate steroid hormone receptors |
| 02/02/2006 | US20060025569 Microwave-assisted peptide synthesis |
| 02/02/2006 | US20060025568 Microwave-assisted peptide synthesis |
| 02/02/2006 | US20060025567 Deprotecting amino acid linked to solid phase resin by admixing with solution in transparent vessel while irradiating with microwaves, coupling/activating/hybridizing amino acids, then cleaving |
| 02/02/2006 | US20060025345 Substituted ethane-1,2-diamines for the treatment of Alzheimer's disease |
| 02/02/2006 | US20060024761 Protein biopolymer markers predictive of alzheimer's disease |
| 02/02/2006 | US20060024334 Immunotherapeutic methods and systems |
| 02/01/2006 | EP1621554A1 Immunoglobulins devoid of light chains |
| 02/01/2006 | EP1621546A1 Peptide ligands specific to immonoglobulins |
| 02/01/2006 | EP1620135A1 In vivo imaging using peptide derivatives |
| 02/01/2006 | EP1620130A1 Prodrugs cleavable by cd26 |
| 02/01/2006 | EP1620056A2 Tumor cytotoxicity induced by modulators of the cxcr4 receptor |
| 02/01/2006 | EP1485406A4 Highly homogeneous molecular markers for electrophoresis |
| 02/01/2006 | CN1729202A Targeting single epitopes |
| 02/01/2006 | CN1727008A Gas bearing activator of dry powder in use for diagnosing and/or treating thrombus |
| 01/31/2006 | US6992176 Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| 01/31/2006 | US6992169 Drug moiety linked to a carrier moiety comprising a homeobox peptide or a fragment or derivative thereof. |
| 01/31/2006 | US6992081 Such as 4-((6-(3,5-difluoro-phenyl)-5-(S)-(3-dipropylcarb-amoyl-benzoyl-amino)-2-(R)-ethyl-4-(S)-hydroxy-hexanoylamino)-methyl)-cyclohexanecarboxylic acid for inhibiting secretase activity and cleavage of amyloid precursor protein |
| 01/31/2006 | US6991908 Antiobestic agents methods for screening antiobestic agents and kits comprising same |
| 01/31/2006 | US6991775 Peptide-based multimeric targeted contrast agents |
| 01/30/2006 | CA2510809A1 Chimpanzee trace amine associated receptors |
| 01/26/2006 | WO2006009888A2 C-met kinase binding proteins |
| 01/26/2006 | WO2006009836A2 Tdf-related compounds and analogs thereof |
| 01/26/2006 | WO2006008266A2 Factor xi-binding proteins |
| 01/26/2006 | WO2005105829A3 Caspase-2 inhibitors and their biological applications |
| 01/26/2006 | WO2005079747A8 Pharmaceutical preparation for the oral cavity |
| 01/26/2006 | WO2005019421A3 Crosslinking within coordination complexes |
| 01/26/2006 | WO2005005462A3 Blys antagonists and uses thereof |
| 01/26/2006 | US20060020110 Synthetic peptides that bind to the hepatitis B virus core and E antigens |
| 01/26/2006 | US20060019904 Composition for promoting lacrimal secretion |
| 01/26/2006 | US20060019902 PTH-like peptides |
| 01/26/2006 | US20060019901 Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| 01/26/2006 | US20060019900 Alpha-4 beta-1 integrin ligands for imaging and therapy |
| 01/26/2006 | US20060019892 Conopeptides and methods of use |
| 01/26/2006 | US20060019885 Modified bryodin 1 with reduced immunogenicity |
| 01/26/2006 | US20060019309 Self-assembling peptide surfaces for cell patterning and interactions |
| 01/26/2006 | US20060018915 Heteroclitic analogs and related methods |
| 01/26/2006 | US20060018903 Tumor necrosis factors (TNF); site-directed mutagenesis, genetic deletions; monoclonal antibodies with decreased immunogenicity and lymphocyte epitopes; major histocompatibility complex binding ligands; for treatment of rheumatoid arthritis and Crohn's disease |
| 01/26/2006 | CA2612303A1 Anti-glycated cd59 antibodies and uses thereof |
| 01/26/2006 | CA2574665A1 Therapeutic and diagnostic agents |
| 01/26/2006 | CA2571218A1 Tdf-related compounds and analogs thereof |
| 01/25/2006 | EP1619207A2 HLA-A2.1 binding peptides derived from HCV and their uses |
| 01/25/2006 | EP1619202A2 immunotherapeutic methods using epitopes of wt-1 and gata-1 |
| 01/25/2006 | EP1618380A2 N epsilon AND/OR N alpha DERIVATIZED, METAL AND ORGANIC PROTECTED L-HISTIDINE FOR COUPLING TO BIOMOLECULES FOR HIGHLY EFFICIENT LABELING WITH (M(OH2)3(CO)3)+ BY FAC COORDINATION |
| 01/25/2006 | EP1618125A1 Vitamin c derivatives with peptide, preparation method thereof and composition comprising the same |
| 01/25/2006 | EP1618124A2 Prophylactic and therapeutic benefits of new class of immune stimulating peptides |
| 01/25/2006 | EP1494695A4 Plasma protein-binding ligands |
| 01/25/2006 | EP1474430B1 Bi-functionalised metallocenes use for marking biological molecules |
| 01/25/2006 | CN1724561A Series peptide for promoting proliferation of bone marrow karyota and bone marrow substrate cell and its application |
| 01/25/2006 | CN1724560A Antigen simulating epipeptide of C type para chicken blood phili bacillus and its use |
| 01/25/2006 | CN1724559A Antigen simulating epipeptide of A type parachicken blood phili bacillus and its use |
| 01/25/2006 | CN1724558A Series peptide for inhibiting growth of cancer cell and bone marrow karyocyte and its application |
| 01/25/2006 | CN1724066A Controlled release composition and method of producing the same |
| 01/24/2006 | US6989452 Anticancer agents |
| 01/24/2006 | US6989435 Compounds and methods to inhibit or augment an inflammatory response |
| 01/24/2006 | US6989371 Bombesin analogs for treatment of cancer |
| 01/24/2006 | US6989245 Screening for modulator of enzyme activity; diagnosing cancer in mammals; obtain sample containing preferential enzymatic actvity, incuabte with test compound, monitor adjustment in enzyme activity |
| 01/24/2006 | US6989146 Stress proteins and peptides and methods of use thereof |
| 01/24/2006 | US6988446 Purified nitric oxide synthase |
| 01/24/2006 | CA2368431C Melanocortin receptor ligands |
| 01/23/2006 | CA2586086A1 Furin inhibitors |
| 01/19/2006 | WO2006006954A2 Modified fusion peptides derived from a p53 domain against malignant and/or transformed mammalian cells |
| 01/19/2006 | WO2006005592A1 Polypeptide species useful for the treatment of neurological disorders |
| 01/19/2006 | WO2006005589A2 Polypeptide species useful for the treatment of neurological disorders |
| 01/19/2006 | WO2006005588A1 Polypeptide species useful for the treatment of neurological disorders |
| 01/19/2006 | WO2006005585A2 Secreted polypeptide species differentially expressed during pregnancy |
| 01/19/2006 | WO2006005584A1 Polypeptide species useful for the treatment of neurological disorders |
| 01/19/2006 | WO2006005361A1 Peptides liable to bind to the tie2 receptor, nucleic acids encoding them, and their uses |
| 01/19/2006 | WO2005056576A3 Branched peptide amphiphiles, related epitope compounds and self assembled structures thereof |
| 01/19/2006 | US20060014933 Using amines or amino acids as mobile phase modifiers in chromatography |
| 01/19/2006 | US20060014930 Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses |
| 01/19/2006 | US20060014929 Liquid phase peptide synthesis of KL-4 pulmonary surfactant |
| 01/19/2006 | US20060014927 Redox-stable, non-phosphorylated cyclic peptide inhibitors of SH2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use |
| 01/19/2006 | US20060014926 Human papillomavirus E6 and E7 polypeptides, mutant polypeptide retains 30% of the immunogenicity of an isolated polypeptide comprising human wild-type papillomavirus E6 and E7 |
| 01/19/2006 | US20060014697 Pharmaceutical compositions comprised of amino acid, peptide, or oligopeptide attached to an active agent; when delivered at proper dosage composition provides therapeutic activity similar to that of parent active agent; when delivered at higher dose potential for overdose is reduced |
| 01/19/2006 | US20060014696 Modulators of beta-amyloid peptide aggregation comprising D-amino acids |